Shionogi has been awarded a $119 million contract from BARDA for Fetroja, a direct government commitment to the drugmaker’s drug.
BARDA, part of the U.S. Department of Health and Human Services, uses contracts like this to secure access to medical products it considers strategically critical. At $119 million, it’s a real commitment. The revenue is non-dilutive: Shionogi doesn’t give up equity to collect it, and it doesn’t depend on commercial market performance. The government is the payer.
What does the buyer actually get? Fetroja, at $119 million. Contract terms beyond the total value weren’t disclosed, but the dollar commitment alone signals how BARDA has valued its need for this drug.
Diana Kowalski